Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can
help with attention deficits due to traumatic brain injury (TBI). Vyvanse is currently
approved for the treatment of Attention-Deficit/Hyperactivity (ADHD). The exact effects this
drug may have on attention deficits caused by TBI are not known, but we expect that Vyvanse
will be of some help in treating those types of problems as well. The study will utilize
functional magnetic resonance imaging (fMRI) methods, as well as neurobehavioral measures, to
elucidate neural mechanisms of response.